Great Elm Capital Corp. (GECC)·Q4 2024 Earnings Summary
Executive Summary
- Q4 total investment income was $9.1M and NII per share fell to $0.20 from $0.39 in Q3; management attributed the step-down to uneven early-stage CLO JV distributions ($0.5M in Q4 vs $3.2M in Q3) and isolated financing-related expenses including shelf write-off .
- Versus S&P Global consensus, GECC materially missed on Primary EPS/NII per share ($0.20 vs $0.353*) and revenue/TII ($9.23M vs $11.46M*); Q3 was a modest beat on both and Q2 a slight miss (see Estimates Context) .
- The Board raised the quarterly dividend 5.7% to $0.37 for Q1 2025 and paid a $0.05 special distribution; asset coverage improved to 169.7% and net assets rose to $136.1M despite NAV/share declining to $11.79 .
- Management guided confidence in dividend coverage in Q1 and FY 2025, with CLO JV distributions of $3.8M received through March 7, 2025 and an expectation that Q2 2025 distributions will exceed Q1 .
What Went Well and What Went Wrong
What Went Well
- Scale and balance sheet: Net assets increased to $136.1M QoQ; asset coverage ratio improved to 169.7%, with $25M revolver undrawn and cash/money market ~$8.4M .
- Portfolio quality: First-lien secured exposure increased; first-lien loans rose to 71% of the corporate portfolio by year-end and nonaccruals remained <1% of fair value .
- Shareholder returns: Dividend increased to $0.37 for Q1 2025 and a $0.05 special distribution declared in December; management expressed confidence in covering the higher dividend in Q1 and through 2025 .
Quoted: “I am confident that we are well positioned to cover the increased dividend in the first quarter and over 2025.”
What Went Wrong
- Earnings cadence: NII was adversely impacted by uneven CLO JV cash distributions ($0.5M in Q4 vs $3.2M in Q3), typical in early-stage CLO investments .
- Financing charges: NII per share absorbed ~$0.03 impact from charges related to refinancing January 2025 debt maturity and the new shelf registration; the prior shelf deferred expense write-off also hit NII .
- NAV/share compression and revenue shortfall: NAV/share declined to $11.79 from $12.04 QoQ and total investment income of $9.1M missed consensus, reflecting timing drag from equity raises and CLO JV ramp .
Financial Results
Core Financials (USD, per quarter; older → newer)
Actuals vs Consensus (S&P Global; Primary EPS maps to NII/share for BDCs)
Values retrieved from S&P Global. Primary EPS reflects NII per share for BDCs.*
Segment/Investment Mix (fair value; Q3 vs Q4)
Note: In Q2 2024, the CLO JV was included among “dividend paying equity investments” totaling ~$43.7M (14.7% of total); corporate credit was $190.0M (63.8%) and GESF debt/equity were $29.7M/ $15.0M (10.0%/5.0%) .
KPIs and Balance Sheet
Guidance Changes
Earnings Call Themes & Trends
Management Commentary
- “During the fourth quarter, NII was primarily impacted by the uneven cadence of cash flows from our CLO JV… As the CLO JV grows and matures, we believe the magnitude of this impact should decline in future quarters.” — Matt Kaplan, CEO .
- “We wrote off the deferred expense of our prior shelf registration after filing a new $500 million shelf… should increase our flexibility and reduce our cost of raising debt.” — Keri Davis, CFO .
- “We are encouraged by the early success of our CLO joint venture strategy… targeting high teens to 20% returns over time.” — Matt Kaplan, CEO .
- “We made the decision to consolidate all ABL operations under one roof, rebranding as Great Elm Commercial Finance… repositioning [legacy] Healthcare Finance to focus solely on health care real estate financing.” — Michael Keller, President GESF .
Q&A Highlights
- CLO JV concentration and diversification: Currently invested with Apex; majority positions via JV; potential diversification over time .
- CLO arbitrage amid spread compression: Liability costs also compressed; modeled IRRs high teens to ~20%; emphasize uneven initial distributions but improving on a trailing-12-month basis .
- Credit monitoring: Maverick Gaming mark discussed; position evaluated quarterly with third-party valuation specialists; limited disclosure due to private status .
- JV scale target: CLO exposure could reach ~20% of asset base over time as platform scales .
- Deployment outlook: Seeing secondary loan opportunities as spreads widen; steady direct lending pipeline; limited near-term repayments; M&A timing uncertain due to tax policy clarity .
Estimates Context
- Q4 2024 misses: Primary EPS/NII per share actual $0.20 vs $0.3533 consensus*; revenue/TII actual $9.231M vs $11.4567M consensus* .
- Q3 2024 beats: NII/share $0.39 vs $0.3567*; revenue/TII $11.727M vs $11.021M* .
- Q2 2024 slight misses: NII/share $0.32 vs $0.34*; revenue/TII $9.548M vs $9.6837M* .
Values retrieved from S&P Global. Primary EPS reflects NII per share for BDCs.*
Where estimates may adjust: Analysts likely lift forward NII assumptions for Q1–Q2 2025 given $3.8M CLO JV distributions received through March 7, 2025 and management’s expectation for higher Q2 distributions; however, early-stage CLO lumpiness and financing costs warrant conservative near-term cadence assumptions .
Key Takeaways for Investors
- Q4 was a reset quarter driven by CLO JV distribution timing and financing charges; the structural drivers (scale, CLO growth) remain intact and supportive of higher NII in 2025 .
- The 5.7% dividend increase to $0.37 signals confidence; management explicitly guides to coverage in Q1 and through FY 2025, supported by stronger CLO JV cash flows .
- Asset coverage improved and liquidity is solid (undrawn $25M revolver), providing capacity to fund JV commitments and measured deployment into secondary and direct lending opportunities .
- Portfolio quality strengthened with higher first-lien exposure and nonaccruals <1% of FV; credit monitoring remains vigilant amid macro uncertainty .
- Expect estimate revisions to reflect lumpy but rising CLO distributions (Q2 > Q1 per management), with potential upward bias to NII run-rate beyond Q1 .
- Near-term trading: Stock may be sensitive to reported misses vs Q4 consensus and NAV/share compression; catalysts include confirmation of Q1 dividend coverage and disclosure of Q2 distribution trajectory .
- Medium-term: As CLO JV scales and equity-raise deployment drag fades, TII/NII cadence should smooth, supporting valuation re-rating closer to NAV contingent on sustained coverage and credit performance .